Capecitabine and vinorelbine in elderly patients (≥65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
Dagmar Hess(Kantonsspital St. Gallen), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Stefan Aebi(University of Lucerne), Daniel Rauch(Washington University in St. Louis), Pierluigi Ballabeni(Swiss Group For Clinical Cancer Research), Beat Thürlimann(University of St.Gallen), Olivia Pagani(Swiss Group For Clinical Cancer Research), B. Rufener(Swiss Group For Clinical Cancer Research), Monica Castiglione‐Gertsch(University of Geneva)
Cited by 29
Related Papers
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k